Drug intelligence / Profile preview

Leptivia

Development stage: Unknown
Lead developer: ORxPharma
Modality: Small Molecules
Administration: Oral

Overview

Leptivia is an oral controlled-release small-molecule obesity candidate being developed by ORxPharma. The product is described by the company as a repurposed existing drug molecule formulated for controlled release, with a proposed mechanism centered on promoting satiety and suppressing appetite to support weight loss. No specific molecular target or active ingredient has been publicly disclosed in the provided source material. The program is listed in Phase 1 development for obesity.

Brand names: Leptivia
Other names: Leptivia CR

Beyond the preview

Go deeper on Leptivia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leptivia.

Explore the full profile